Exagen Inc. Gains 37.82%
Exagen Inc. (XGN:NASDAQ) rocketted at $6.45, a gain of 37.8%. On Tue, Aug 04, 2026, XGN:NASDAQ touched a New 2-Week High of $6.45. The stock appeared on our News Catalysts scanner on Tue, Aug 04, 2026 at 05:59 PM in the 'MISCELLANEOUS' category. From Tue, Jul 21, 2026, the stock recorded 60.00% Up Days and 63.64% Green Days
About Exagen Inc. (XGN:NASDAQ)
Exagen Diagnostics Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
Top 10 Gainers:
- Autonomix Medical, Inc. (AMIX:NASDAQ), 434.25%
- Adagio Medical Holdings, Inc. (ADGM:NASDAQ), 73.91%
- China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), 60.08%
- Direxion Daily PLTR Bull 2X Shares (PLTU:NASDAQ), 57.87%
- Elong Power Holding Limited (ELPW:NASDAQ), 51.95%
- Ibotta, Inc. (IBTA:NYSE), 51.91%
- GlucoTrack, Inc. (GCTK:NASDAQ), 44.28%
- Exagen Inc. (XGN:NASDAQ), 37.82%
- Ensysce Biosciences, Inc. (ENSC:NASDAQ), 37.17%
- Telesat Corporation (TSAT:NASDAQ), 36.26%